Moderna RSV vaccine shown to give strong protection against serious cases in adults 50 and older

Moderna's vaccine against respiratory syncytial virus (RSV) has been shown to provide strong protection against serious cases of the infection in adults aged 50 and older, according to a CIDRAP news item published on 11 November 2026.

The text available for this report consists only of the headline. It gives no details of the underlying data, including the study design, the number of participants, the size of the protective effect, the definition of a serious case or any regulatory decision.

LungDaily will update this report if further information from the original CIDRAP article or from Moderna becomes available.